BYON 4413
Alternative Names: BYON-4413Latest Information Update: 20 Jun 2024
At a glance
- Originator Byondis
- Class Antibodies; Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates
- Mechanism of Action Alkylating agents; DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 20 Jun 2024 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in Spain (IV) (NCT06359002)
- 10 Jun 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Spain (IV) (NCT06359002)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)